Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin - Wikidata - awgldk - TriplyDB

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

http://www.wikidata.org/entity/Q35912661

about

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams Gender analysis of moxifloxacin clinical trials Recent advances in tuberculosis: New drugs and treatment regimens.Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Current development and future prospects in chemotherapy of tuberculosis Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats.Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.Advances in Drug Discovery and Development for Pediatric Tuberculosis.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.10 years' experience with the pneumococcal quinolone moxifloxacin.Emerging drugs for the treatment of tuberculosis.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.New treatment options for multidrug-resistant tuberculosis.Caring for children with drug-resistant tuberculosis: practice-based recommendations.Pharmaceutical applications of the Calu-3 lung epithelia cell line.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Optimizing the clinical pharmacology of tuberculosis medications.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa.Concomitant use of voriconazole and rifabutin in a patient with multiple infections.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

P2860

Q24631021-E395299B-0169-4512-B9AA-8F1D66AD8699 Q28538319-F95C486A-F5A1-42E8-B688-26B9C6429583 Q30360811-6D1F9E05-0E5F-43B2-9EFA-41F40D67D76C Q30383012-AED36BAB-F9D4-40FB-8A97-C96D950A8BD4 Q30834393-D6953B1C-AE23-4D00-B4F7-2944043F1F81 Q34150929-CCC90248-CB7E-46C5-8999-8040E3ADCF6A Q35617587-26981993-B025-4CBA-8633-39708082CC21 Q35705874-34F700B5-C393-4CEF-9D2B-08701CF7785C Q35974112-F172CCE7-D835-47B5-9049-2FB473498649 Q36482760-1D01949E-1B56-4A02-AD9D-EC68CA757674 Q36675409-E140C181-44DB-4BBE-B3B8-179B99FB207D Q36728692-2E5104F1-34BE-4330-84F1-510C6F3853DE Q36949454-47E476FE-6104-4316-8084-3320EE1C46D2 Q37134041-3CD16C03-5C1C-4F99-9D84-C88C07CE95D4 Q37346929-20B14877-6326-46BF-B89B-9734C00DA04F Q37579919-1C49F015-0E30-47D4-A881-8A41438A29E5 Q37792105-0F6170BB-FA06-4EF2-8D50-D6FEE07122AB Q37799461-ADDE3C98-3B33-4BD3-A6B2-FC89D15B6783 Q38024041-689B8BB4-7DC2-4665-8BAF-1E2BE955713A Q38043978-842AFE81-DEC7-4116-B9DA-9FCB24EDC64A Q38111427-F1C5A680-8CA9-4455-B565-57D82D545B43 Q38213320-49512D2C-966B-424F-A19E-D58054370F10 Q38542159-2EB6890D-337F-4EDC-870F-0214D7E37A5D Q38973113-C245E7EE-B23B-4DB0-BEFE-26F02E2FDE1E Q39456569-B212B5A0-FC3F-4497-8313-39BF47E37DE7 Q41840976-DD944CDB-915C-450D-884E-1804CE1CF46C Q42189720-2985BB6F-25E5-469E-906D-3FD715F1A0FD Q43075165-D8EE0748-1C97-4AE9-BE8F-1AD0E8A835D7 Q43253700-0E42864C-ECC9-40E5-99E4-2E16B8299E75 Q44237338-9029EFF2-44CD-47CD-9370-667506091ACF Q44461729-85945543-85D5-499C-820F-AE2EA967E58D Q47332682-BDFA0313-A3D1-4573-9288-3C9418A4C123 Q49792134-0CA4A396-1F1E-420A-A342-CA2B0A38874A Q50054098-37169C82-2E57-441A-9CC6-F2429A18BA23

P2860

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

http://www.wikidata.org/entity/Q35912661

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Effects of rifampin and multid ...... concentrations of moxifloxacin

@ast

Effects of rifampin and multid ...... concentrations of moxifloxacin

@en

type

label

Effects of rifampin and multid ...... concentrations of moxifloxacin

@ast

Effects of rifampin and multid ...... concentrations of moxifloxacin

@en

prefLabel

Effects of rifampin and multid ...... concentrations of moxifloxacin

@ast

Effects of rifampin and multid ...... concentrations of moxifloxacin

@en

P1433

Q35912661-62DB0892-32AA-4A74-8A08-40C177260D6A

P1476

Q35912661-5D83D0C7-C0FB-439A-B2F9-6102FDCB7B0E

P2093

Q35912661-2DE9C0E0-30B9-4BC5-AF8D-DFAB07A1E4B2

Q35912661-36A05973-4665-4687-99DF-3D7C62A9078C

Q35912661-3C69CFF8-8651-4334-93E7-4F61DF47DE97

Q35912661-3FBDEB06-FA05-45AE-A54B-D96B52044C07

Q35912661-71434B6C-F06A-428D-A988-3D16A8B4AE32

Q35912661-8F370E5A-BC36-4523-97A7-F069335CDFF8

Q35912661-90E82371-E8DE-4647-B4F7-FBFFFA9C8591

Q35912661-9707F06B-B53A-4E0C-9647-6778E566B968

P2860

Q35912661-04FC8383-B045-4513-B32D-5000A9D69E35

Q35912661-162CA2BE-9791-41C8-BD51-048153A808B6

Q35912661-3449FFC3-AD15-416C-891F-CB63DC29DCCE

Q35912661-464A72A0-0F80-43D8-8B5C-8378B448253B

Q35912661-4ADEF366-107A-4697-A187-B82DF592DD8F

Q35912661-53946206-664C-4E53-A775-77053695AE85

Q35912661-73F94A29-58A3-42CC-B5F1-6A4BFF857E2F

Q35912661-82C462F8-02C3-4CE5-8C11-2A5EF6BF47D2

Q35912661-B305070E-0808-4B69-A4EB-076EB2E7757F

Q35912661-BBDB344A-E677-407D-9BE9-F89B39D2E9EF

P304

Q35912661-8C704455-57EC-4796-96E3-64E4739D96AC

P31

Q35912661-B27DC260-C066-4A69-99E1-B00A6144D404

P356

Q35912661-E6EF847B-584F-4842-8732-233EB2354A39

P407

Q35912661-991187C3-7FBA-49F3-A912-3BFDA34E03E0

P433

Q35912661-79AEB94B-0950-4AEE-A2AA-8311F79985E0

P478

Q35912661-05D0C610-2421-4793-8B70-5ECEFE2B0990

P577

Q35912661-7FCD7096-33FF-49CC-8CE2-1E9C3DEA7D94

P698

Q35912661-DA5E6700-1FB7-4D28-A225-E0AB94F9CC66

P921

Q35912661-76442DC2-D70D-44D0-9245-1CE8A3C2F62E

P932

Q35912661-098E7D8A-8A1C-40AD-A4B6-2E8EB4878DE2

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Effects of rifampin and multid ...... concentrations of moxifloxacin

@en

P2093

Andrew Vernon

http://www.w3.org/2001/XMLSchema#string

Charles A Peloquin

http://www.w3.org/2001/XMLSchema#string

Chi-Cheng Luo

http://www.w3.org/2001/XMLSchema#string

Marc Weiner

http://www.w3.org/2001/XMLSchema#string

Melissa Engle

http://www.w3.org/2001/XMLSchema#string

Stefan Goldberg

http://www.w3.org/2001/XMLSchema#string

Vipin Agarwal

http://www.w3.org/2001/XMLSchema#string

William Burman

http://www.w3.org/2001/XMLSchema#string

P2860

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function.

Clinical aspects of the MDR1 (ABCB1) gene polymorphism.

Pharmacogenetics of drug transporters and its impact on the pharmacotherapy.

Pharmacokinetic drug interactions with rifampicin.

Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients

Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line.

P304

2861-2866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01621-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17517835

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

1932492

http://www.w3.org/2001/XMLSchema#string